Page 94 - Read Online

Qu et al. Hepatoma Res 2020;6:38 I http://dx.doi.org/10.20517/2394-5079.2020.12 Page 7 of 7

cell therapy. Cancer Cell 2017;31:711-23.e4.
44. Zhu AX, Finn RS, Edeline J, Cattan S, Ogasawara S, et al. Pembrolizumab in patients with advanced hepatocellular carcinoma previously
treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial. Lancet Oncol 2018;19:940-52.
45. El-khoueiry AB, Sangro B, Yau T, Crocenzi TS, Kudo M, et al. Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate
040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial. Lancet 2017;389:2492-502.
46. Sia D, Jiao Y, Martinez-Quetglas I, Kuchuk O, Villacorta-Martin C, et al. Identification of an immune-specific class of hepatocellular
carcinoma, based on molecular features. Gastroenterology 2017;153:812-26.
47. Harding JJ, Nandakumar S, Armenia J, Khalil DN, Albano M, et al. Prospective genotyping of hepatocellular carcinoma: clinical
implications of next-generation sequencing for matching patients to targeted and immune therapies. Clin Cancer Res 2019;25:2116-26.
48. Ruiz de Galarreta M, Bresnahan E, Molina-Sánchez P, Lindblad KE, Maier B, et al. β-catenin activation promotes immune escape and
resistance to anti-PD-1 therapy in hepatocellular carcinoma. Cancer Discov 2019;9:1124-41.
49. Di Tommaso L, Sangiovanni A, Borzio M, Park YN, Farinati F, et al. Advanced precancerous lesions in the liver. Best Pract Res Clin
Gastroenterol 2013;27:269-84.
50. Grimm CF, Ortmann D, Mohr L, Michalak S, Krohne TU, et al. Mouse alpha-fetoprotein-specific DNA-based immunotherapy of
hepatocellular carcinoma leads to tumor regression in mice. Gastroenterology 2000;119:1104-12.
51. Hong Y, Peng Y, Guo ZS, Guevara-Patino J, Pang J, et al. Epitope-optimized alpha-fetoprotein genetic vaccines prevent carcinogen-
induced murine autochthonous hepatocellular carcinoma. Hepatology 2014;59:1448-58.
52. Geissler M, Mohr L, Weth R, Kohler G, Grimm CF, et al. Immunotherapy directed against alpha-fetoprotein results in autoimmune liver
disease during liver regeneration in mice. Gastroenterology 2001;121:931-9.
53. Filmus J, Capurro M. Glypican-3: a marker and a therapeutic target in hepatocellular carcinoma. FEBS J 2013;280:2471-6.